Research & Development
Our project portfolio currently consists of three projects, Strangvac®, INV-274 and Novel Antigen for S. aureus. The development of the company’s first vaccine candidate, Strangvac®, which is a vaccine against strangles, has gone through clinical trials. Good protective effect against a disease, that has lacked both a safe and effective vaccine, was demonstrated.
The technology platform is based on research at the Karolinska Institute and the Swedish University of Agricultural Sciences and the company’s first vaccine candidate, Strangvac®, is developed with this technology. The technology is based on recombinant proteins instead of killed, or attenuated microorganisms, which are used in conventional vaccines. This reduces the risk of serious side effects. The concept used, to link together the most important parts of various bacterial surface proteins to fusion proteins, is suited also for other future vaccines in the same way as Strangvac®. In this way, several key surface proteins are incorporated into a small number of vaccine components.
The company owns four patent families. The patent families include a total of 23 issued patents in various countries and seven additional patents pending. These patents have the primary objective of protecting the company’s vaccine product (s) Strangvac®. Along with the positive results of the clinical studies, we have demonstrated a “proof of concept” for our core technology.
Overall, Intervacc possess technology, in-house expertise and strategic collaborations to take a project from the research stage to the finished product.